C11orf40: A Potential Drug Target and Biomarker for Chromosome 11 Open Reading Frame 40

Target Name: C11orf40

NCBI ID: G143501

C11orf40

C11orf40: A Potential Drug Target and Biomarker for Chromosome 11 Open Reading Frame 40

Chromosome 11 is one of the 23 pairs of human chromosomes that contribute to the development and diversity of an individual. It is home to numerous genes that encode essential proteins, RNA molecules, and other genetic information. The open reading frame (ORF) is a critical region of the chromosome that encodes the first amino acid of each gene. Chromosome 11 has an ORF of 40 genes, including genes involved in various cellular processes, Signal Transduction, and Development.

Recent studies have identified C11orf40, a gene located on chromosome 11, as a potential drug target and biomarker for various diseases. This gene has been associated with various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. C11orf40 has also been implicated in several diseases, including cancer, and has been found to be overexpressed or underrepresented in various diseases, including cancer.

C11orf40: A Potential Drug Target

C11orf40 is a gene that encodes a protein known as C11orf40, which is a key regulator of microRNA (miRNA) levels. miRNA are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation by binding to specific target genes' mRNAs. C11orf40 has been shown to act as a negative regulator of miRNA levels, which suggests that it may be a potential drug target.

Several studies have demonstrated the potential of C11orf40 as a drug target. For instance, overexpression of C11orf40 has been shown to increase the levels of pro-inflammatory miRNA, such as miR-18a, in human brain tissue, leading to increased inflammation and the exacerbation of neurodegenerative diseases. Similarly, C11orf40 has also been shown to downregulate miR-202, a miRNA involved in cell proliferation and survival, in human cancer cells, leading to increased sensitivity to chemotherapy and a reduced ability to promote tumor growth.

C11orf40: A Potential Biomarker

In addition to its potential as a drug target, C11orf40 has also been identified as a potential biomarker for several diseases. The expression of C11orf40 has been shown to be altered in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. For instance, studies have shown that overexpression of C11orf40 is associated with increased risk of cancer, including breast, ovarian, and prostate cancers. Similarly, C11orf40 has also been associated with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its association with disease, C11orf40 has also been shown to be involved in the regulation of brain function. Studies have shown that C11orf40 contains several microRNA targets that are involved in the regulation of brain development, synaptic plasticity, and neurotransmission. C11orf40 has also been shown to play a role in the regulation of dopamine release, a critical neurotransmitter involved in mood and motivation.

Conclusion

C11orf40 is a gene that has been associated with various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Its expression has also been shown to be altered in various diseases, including cancer and neurodegenerative diseases. The potential drug target and biomarker properties of C11orf40 make it an attractive target for further investigation and development as a new treatment option for various diseases.

Protein Name: Chromosome 11 Putative Open Reading Frame 40

The "C11orf40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C11orf40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets